Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$33.31−0.08 (-0.24%)
Close on Nov 20, 2026Market cap $2.20BP/E 6.2Yield –
Lakefront Biotherapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was €1.08B, up 349.6% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €1.08B | +349.6% |
| FY2024 | Dec 31, 2024 | €240.79M | +5.1% |
| FY2022 | Dec 31, 2022 | €229.17M | -1.5% |
| FY2021 | Dec 31, 2021 | €232.76M | – |
See a number that looks wrong?